Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05788081
Title Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. (TOP-FLOR)
Acronym TOP-FLOR
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Olivia Newton-John Cancer Research Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS


No variant requirements are available.